GPT Healthcare

Why is GPT Healthcare Ltd falling/rising?

As of 10-Jun, GPT Healthcare Ltd's stock price is 148.45, down 1.0%, but it has gained 3.33% over the last two days and outperformed its sector today. Despite a year-over-year decline of 3.04%, it has a positive year-to-date return of 5.85%, although decreasing investor participation may be affecting its current price.

As of 10-Jun, GPT Healthcare Ltd's stock price is currently at 148.45, reflecting a decrease of 1.5 points or 1.0%. Despite this decline, the stock has shown some positive trends in recent performance. Over the last two days, it has gained 3.33%, indicating a short-term upward movement. Additionally, it has outperformed its sector by 0.92% today.<BR><BR>In terms of longer-term performance, the stock has increased by 2.84% over the past month, contrasting with a decline of 4.33% in the benchmark Sensex during the same period. Year-to-date, GPT Healthcare Ltd has a positive return of 5.85%, while the Sensex has fallen by 13.19%. However, over the past year, the stock has decreased by 3.04%, which is still better than the Sensex's decline of 10.21%.<BR><BR>Despite these positive indicators, there are signs of falling investor participation, as the delivery volume has decreased by 10.9% compared to the 5-day average. This decline in trading activity could be contributing to the current drop in stock price. Nevertheless, GPT Healthcare is trading above its moving averages across various time frames, suggesting a generally favorable trend in the stock's performance.

What does GPT Healthcare do?

GPT Healthcare Ltd is a micro-cap company in the hospital industry, reporting net sales of 126 Cr and a net profit of 15 Cr for March 2026, with a market cap of INR 1,225 Cr. The company has a P/E ratio of 29.00 and a dividend yield of 1.66%.

Overview: <BR>GPT Healthcare Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>GPT Healthcare Ltd was originally incorporated as "Jibansatya Printing House Private Limited" in 1989. The company changed its name to "GPT Healthcare Private Limited" in 2005 and later converted to a public company, adopting the name "GPT Healthcare Limited" in 2021. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 126 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 15 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,225 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 1.66% <BR>Debt-Equity: 0.25 <BR>Return on Equity: 16.64% <BR>Price to Book: 4.87 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Which are the latest news on GPT Healthcare?

How big is GPT Healthcare?

As of 10th June, GPT Healthcare Ltd has a market capitalization of 1,225.00 Cr, with recent net sales of 472.55 Cr and a net profit of 42.22 Cr. Shareholder's funds are 158.18 Cr, and total assets amount to 319.51 Cr as of March 2022.

As of 10th June, GPT Healthcare Ltd has a market capitalization of 1,225.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, GPT Healthcare reported Net Sales of 472.55 Cr and a Net Profit of 42.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2022, with Shareholder's Funds amounting to 158.18 Cr and Total Assets of 319.51 Cr.

Who are the peers of the GPT Healthcare?

Peers of GPT Healthcare include Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, Asarfi Hospital, Unihealth Hosp, Chandan Healthcare, and Aprameya Enginee. GPT Healthcare has excellent management and capital structure but below-average growth, with a 1-year return of -3.40%, compared to KMC Speciality's 75.31% and Indrapr.Medical's -9.19%.

Peers: The peers of GPT Healthcare are Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, Asarfi Hospital, Unihealth Hosp, Chandan Healthca, and Aprameya Enginee.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, Asarfi Hospital, Unihealth Hosp, Chandan Healthca, and the rest. Growth is Excellent at Artemis Medicare, Dr Agarwal's Eye, Unihealth Hosp, and Chandan Healthca, while Good growth is noted at Indrapr.Medical, KMC Speciality, and Asarfi Hospital, and Below Average growth is seen at Shalby and GPT Healthcare. Excellent capital structure is present at GPT Healthcare, Indrapr.Medical, KMC Speciality, and Unihealth Hosp, while Good capital structure is found at Artemis Medicare, Shalby, Asarfi Hospital, and Aprameya Enginee.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 75.31%, while Indrapr.Medical has the lowest at -9.19%, with GPT Healthcare's 1-year return at -3.40% being higher than Indrapr.Medical's but lower than KMC Speciality's. Additionally, Shalby and Indrapr.Medical have negative six-month returns.

Are GPT Healthcare Ltd latest results good or bad?

GPT Healthcare Ltd's latest results show strong revenue growth of 24.63% year-on-year, with a net profit increase of 55.50%. However, declining operating and profit margins raise concerns about profitability and cost management.

GPT Healthcare Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹14.57 crores for Q4 FY26, which is a significant increase of 55.50% compared to the previous quarter. Additionally, revenue grew by 24.63% year-on-year, reaching ₹126.37 crores, indicating strong top-line momentum.<BR><BR>However, there are concerns regarding profitability. The operating margin has declined to 18.49% from 20.40% a year ago, reflecting rising costs that are impacting profitability despite the strong revenue growth. The profit after tax (PAT) margin also decreased to 11.53%, down from 12.71% in the same quarter last year.<BR><BR>Overall, while the revenue growth is impressive and suggests robust demand, the compression in margins and the volatility in profit levels raise questions about the company's cost management and sustainability of profit growth. Therefore, the results can be seen as good in terms of revenue expansion but concerning regarding profitability metrics.

Should I buy, sell or hold GPT Healthcare Ltd?

When is the next results date for GPT Healthcare Ltd?

The next results date for GPT Healthcare Ltd is 18 May 2026.

The next results date for GPT Healthcare Ltd is scheduled for 18 May 2026.

How has been the historical performance of GPT Healthcare?

GPT Healthcare experienced significant growth from March 2021 to March 2022, with net sales increasing to 337.42 Cr from 242.75 Cr, and profit after tax rising to 41.66 Cr from 21.09 Cr, reflecting improved operating margins and cash flow. Total liabilities grew slightly, while shareholder's funds increased, indicating overall financial strength.

Answer:<BR>The historical performance of GPT Healthcare shows significant growth from March 2021 to March 2022.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2022, GPT Healthcare reported net sales of 337.42 Cr, an increase from 242.75 Cr in the previous year. The total operating income also rose to 337.42 Cr from 242.75 Cr. Total expenditure, excluding depreciation, increased to 263.58 Cr from 193.76 Cr, driven by higher raw material costs and employee expenses. Operating profit, excluding other income, improved to 73.84 Cr from 48.99 Cr, leading to an operating profit margin of 21.88%, up from 20.18%. Profit before tax surged to 54.08 Cr from 28.88 Cr, resulting in a profit after tax of 41.66 Cr, compared to 21.09 Cr the previous year, reflecting a PAT margin increase to 12.35% from 8.69%. On the balance sheet, total liabilities grew to 319.51 Cr from 310.61 Cr, while shareholder's funds increased to 158.18 Cr from 133.87 Cr. Cash flow from operating activities rose to 65.00 Cr from 42.00 Cr, contributing to a closing cash and cash equivalent of 8.00 Cr, up from 4.00 Cr. Overall, GPT Healthcare demonstrated robust growth across key financial metrics during this period.

Is GPT Healthcare technically bullish or bearish?

As of November 4, 2025, GPT Healthcare's trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, along with negative year-to-date and annual returns compared to the Sensex.

As of 4 November 2025, the technical trend for GPT Healthcare has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the bearish MACD on the weekly time frame, bearish signals from the Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily time frame. The stock has also shown negative returns year-to-date and over the past year compared to the Sensex, reinforcing the bearish outlook.

Is GPT Healthcare overvalued or undervalued?

As of August 7, 2025, GPT Healthcare is considered very attractive and undervalued, with a PE ratio of 27.73, an EV to EBITDA of 15.96, and a ROCE of 26.05%, making it a compelling investment opportunity despite a year-to-date stock decline of 11.93% compared to the Sensex's 3.18% gain.

As of 7 August 2025, GPT Healthcare's valuation grade has moved from attractive to very attractive, indicating a positive shift in its market perception. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 27.73, an EV to EBITDA of 15.96, and a ROCE of 26.05%. <BR><BR>In comparison with peers, GPT Healthcare's PE ratio is significantly lower than that of Max Healthcare, which stands at 108.4, and Apollo Hospitals at 71.36, highlighting its relative value in the market. Despite recent stock performance showing a decline of 11.93% year-to-date compared to a 3.18% gain in the Sensex, the underlying fundamentals suggest that GPT Healthcare offers a compelling investment opportunity in the hospital industry.

Who are the top shareholders of the GPT Healthcare?

The top shareholders of GPT Healthcare include Gpt Sons Private Limited with 65.57%, mutual funds at 6.65%, foreign institutional investors at 4.48%, and Aditya Birla Sun Life Insurance Company Limited with 3.5%. Individual investors own 15.55%, and there are no pledged promoter holdings.

The top shareholders of GPT Healthcare include Gpt Sons Private Limited, which holds the largest stake at 65.57%. Other significant shareholders are mutual funds, which collectively account for 6.65% of the shares, and foreign institutional investors (FIIs), holding 4.48%. The highest public shareholder is Aditya Birla Sun Life Insurance Company Limited, with a 3.5% stake. Additionally, individual investors own 15.55% of the company. There are no pledged promoter holdings reported.

Has GPT Healthcare declared dividend?

GPT Healthcare Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of November 28, 2024. While the company has announced a dividend, total returns have varied, showing a -19.29% return over the last 6 months and an 8.01% return over the past year.

GPT Healthcare Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 28 Nov 2024<BR><BR>Dividend Yield: 1.66%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.29%, with a dividend return of 0%, resulting in a total return of -19.29%.<BR><BR>Over the past year, the price return was 6.31%, the dividend return was 1.70%, leading to a total return of 8.01%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, the price return and dividend return were both 0%, leading to a total return of 0.0%.<BR><BR>Over the last 4 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return and dividend return were both 0%, leading to a total return of 0.0%.<BR><BR>Overall, while GPT Healthcare has declared a dividend, the total returns over various periods show mixed performance, with significant losses in the short term and minimal returns in the longer term.